pyrazines has been researched along with Diabetic Angiopathies in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andersson, C; Mogensen, UM; Scheller, NM; Torp-Pedersen, C; Vaag, A | 1 |
| Cappuccio, F; Ceriello, A; Genovese, S; Schnell, O; Standl, E; Valensi, P | 1 |
| Bando, YK; Ishizu, T; Kodama, K; Murohara, T; Node, K; Oyama, J; Sato, Y | 1 |
| Eurich, DT; McAlister, FA; Minhas-Sandhu, JK; Senthilselvan, A; Weir, DL | 1 |
| Bhatt, DL; Cavender, MA | 1 |
| Atsumi, T; Ishizu, A; Kusunoki, Y; Miyoshi, A; Miyoshi, H; Nakamura, A; Nakazawa, D; Shida, H; Tomaru, U; Yamada, M | 1 |
| Fonseca, VA; John-Kalarickal, J; Wani, JH | 1 |
| Akiyama, E; Fujisue, K; Hokimoto, S; Iwashita, S; Jinnouchi, H; Kaikita, K; Kurokawa, H; Maeda, H; Matsubara, J; Ogawa, H; Ohba, K; Sugiyama, S; Yamamoto, E | 1 |
| Satoh, K | 1 |
| Nakamura, J | 1 |
| Hotta, N | 1 |
| Baum, RP; Hertel, A; Hör, G; Schröder, O | 1 |
| Cañadell Vidal, J | 1 |
4 review(s) available for pyrazines and Diabetic Angiopathies
| Article | Year |
|---|---|
Type 1 diabetes and cardiovascular disease.
Topics: Antihypertensive Agents; Autonomic Nervous System Diseases; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Diabetic Neuropathies; Drug Therapy, Combination; Exenatide; Exercise Therapy; Glucagon-Like Peptide 1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Insulin; Oxidative Stress; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2013 |
Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review.
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2008 |
[Role of polyol pathway in pathogenesis of diabetic microangiopathy].
Topics: Aldehyde Reductase; Animals; Diabetic Angiopathies; Fructose; Glucose; Glycation End Products, Advanced; Humans; L-Iditol 2-Dehydrogenase; Oxidative Stress; Polymers; Polymorphism, Genetic; Protein Kinase C; Pyrazines; Sorbitol; Spiro Compounds | 2005 |
[Progress on the drug therapy for diabetic microangiopathies: aldose reductase inhibitor].
Topics: Aldehyde Reductase; Animals; Clinical Trials as Topic; Diabetic Angiopathies; Drug Design; Humans; Imidazolidines; Polymers; Polymorphism, Genetic; Pyrazines; Rhodanine; Spiro Compounds; Thiazolidines | 2005 |
2 trial(s) available for pyrazines and Diabetic Angiopathies
| Article | Year |
|---|---|
Rationale and design of a study to evaluate the effects of sitagliptin on atherosclerosis in patients with diabetes mellitus: PROLOGUE study.
Topics: Adult; Atherosclerosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Humans; Prospective Studies; Pyrazines; Research Design; Sitagliptin Phosphate; Triazoles | 2014 |
Combined hyperinsulinaemic glucose clamp and oral acipimox for optimizing metabolic conditions during 18F-fluorodeoxyglucose gated PET cardiac imaging: comparative results.
Topics: Administration, Oral; Coronary Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fluorodeoxyglucose F18; Glucose Clamp Technique; Heart; Humans; Hyperinsulinism; Hypolipidemic Agents; Infusions, Intravenous; Insulin; Male; Middle Aged; Pyrazines; Radiopharmaceuticals; Reproducibility of Results; Tomography, Emission-Computed | 1998 |
8 other study(ies) available for pyrazines and Diabetic Angiopathies
| Article | Year |
|---|---|
All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population.
Topics: Denmark; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Stroke; Treatment Outcome; Triazoles | 2014 |
Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Pyrazines; Retrospective Studies; Risk Factors; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2014 |
Do dipeptidyl peptidase-4 inhibitors increase the risk of heart failure?
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Heart Failure; Humans; Male; Pyrazines; Triazoles | 2014 |
Circulating Neutrophil Extracellular Trap Levels in Well-Controlled Type 2 Diabetes and Pathway Involved in Their Formation Induced by High-Dose Glucose.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; DNA; Dose-Response Relationship, Drug; Extracellular Traps; Glucose; Humans; Hypoglycemic Agents; Middle Aged; Neutrophils; Peroxidase; Polymers; Pyrazines; Pyrroles; Quinazolines; Risk Factors; Spiro Compounds; Time Factors | 2016 |
Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes.
Topics: Aged; Anti-Inflammatory Agents; Biomarkers; C-Reactive Protein; Chi-Square Distribution; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Endothelium, Vascular; Female; Glycated Hemoglobin; Humans; Inflammation Mediators; Linear Models; Logistic Models; Male; Manometry; Middle Aged; Multivariate Analysis; Odds Ratio; Peripheral Arterial Disease; Pyrazines; Risk Factors; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles | 2013 |
Dipeptidyl peptidase-4 inhibitors--emerging player for vascular protection.
Topics: Anti-Inflammatory Agents; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Endothelium, Vascular; Female; Humans; Male; Peripheral Arterial Disease; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
New medications help those with diabetes avoid heart trouble. Drugs mimic the body's natural insulin and glucose controls, but diet and exercise are still keys to controlling the disease.
Topics: Diabetes Mellitus; Diabetic Angiopathies; Exenatide; Heart Diseases; Humans; Hypoglycemic Agents; Metformin; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2007 |
[Clinical trial of glypizide].
Topics: Administration, Oral; Cyclohexanes; Diabetes Mellitus; Diabetic Angiopathies; Diabetic Neuropathies; Diabetic Retinopathy; Drug Evaluation; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Sulfonylurea Compounds | 1974 |